➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Harvard Business School
Medtronic
Johnson and Johnson

Last Updated: June 21, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for IW-1973


Email this page to a colleague

« Back to Dashboard

What is the drug development status for IW-1973?

IW-1973 is an investigational drug.

There have been 7 clinical trials for IW-1973. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Hypertension. The leading clinical trial sponsors are Ironwood Pharmaceuticals, Inc. and [disabled in preview].

There are four US patents protecting this investigational drug and forty international patents.

Recent Clinical Trials for IW-1973
TitleSponsorPhase
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male VolunteersIronwood Pharmaceuticals, Inc.Phase 1
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Inhibitor Praliciguat (IW-1973) in Healthy VolunteersIronwood Pharmaceuticals, Inc.Phase 1
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)Ironwood Pharmaceuticals, Inc.Phase 2

See all IW-1973 clinical trials

Clinical Trial Summary for IW-1973

Top disease conditions for IW-1973
Top clinical trial sponsors for IW-1973

See all IW-1973 clinical trials

US Patents for IW-1973

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IW-1973   Get Started Free sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA)   Get Started Free
IW-1973   Get Started Free sGC stimulators Cyclerion Therapeutics, Inc. (Cambridge, MA)   Get Started Free
IW-1973   Get Started Free sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA)   Get Started Free
IW-1973   Get Started Free sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IW-1973

Drugname Country Document Number Estimated Expiration Related US Patent
IW-1973 Australia AU2014227862 2033-03-15   Get Started Free
IW-1973 Australia AU2019203606 2033-03-15   Get Started Free
IW-1973 Brazil BR112015023349 2033-03-15   Get Started Free
IW-1973 Canada CA2907111 2033-03-15   Get Started Free
IW-1973 China CN105408328 2033-03-15   Get Started Free
IW-1973 China CN108912111 2033-03-15   Get Started Free
IW-1973 China CN109369635 2033-03-15   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Mallinckrodt
AstraZeneca
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.